4-氨基己-5-烯酸
4-氨基己-5-烯酸 性质
| 熔点 | 209℃ |
|---|---|
| 沸点 | 277.7±28.0 °C(Predicted) |
| 密度 | 1.064±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 甲醇（微溶）、水（微溶） |
| 酸度系数(pKa) | 4.36±0.10(Predicted) |
| 形态 | 固体 |
| 颜色 | 米白色 |
| 水溶解性 | Soluble to 100 mM in water |
| 主要应用 | 药物 药物小分子 |
| InChI | 1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9) |
| InChIKey | PJDFLNIOAUIZSL-UHFFFAOYSA-N |
| SMILES | NC(CCC(O)=O)C=C |
4-氨基己-5-烯酸 用途与合成方法
A significant increase in seizure threshold is observed following systemic (i.p.) administration of high (600 or 1200 mg/kg) doses of Vigabatrin. Bilateral microinjection of Vigabatrin (10 μg) into either the anterior or posterior substantia nigra pars reticulata (SNr) also increased seizure threshold, but less markedly than systemic treatment. Focal delivery into the subthalamic nucleus (STN) increased seizure threshold more markedly than either intranigral or systemic administration of Vigabatrin.
Vigabatrin inhibits the uptake of taurine in Caco-2 and MDCK cells to 34% and 53%, respectively, at a concentration of 30 mM. In Caco-2 cells the uptake of Vigabatrin under neutral pH conditions is concentration-dependent and saturable with a Km-value of 27 mM. Vigabatrin is able to inhibit the uptake of taurine in intestinal and renal cell culture models.
安全信息
| 危险品标志 | Xi |
|---|---|
| 危险类别码 | 36/37/38 |
| 安全说明 | 26-36 |
| WGK Germany | 3 |
| RTECS号 | MP7745000 |
| 海关编码 | 2922498050 |
| 存储类别 | 6.1C - 可燃，急性毒性 类别3 毒性化合物或者引起慢性影响的化合物 |
| 危险性类别 | 特异性靶器官毒性-反复接触类别1 |
| 毒害物质数据 | 68506-86-5(Hazardous Substances Data) |
| 毒性 | LD50 oral in rat: 3gm/kg |
4-氨基己-5-烯酸 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-15399 | 4-氨基己-5-烯酸 | 68506-86-5 | 5 mg | 500 |
| 2026-09-15 | HY-15399 | 4-氨基己-5-烯酸 | 68506-86-5 | 10 mM * 1 mL in Water | 550 |
